explored the relationship between mutation profile and PD-L1 expression and found that tumors with TP53 mutation in the NSCLC cohort had significantly higher PD-L1 expression (p = 0.01), though this was not observed in the CRC cohort (p = 0.5). The gene discussed is TP53; the disease is non-small cell lung carcinoma.